Formula (I) {Wherein, A is a sulfur atom, an oxygen atom, the formula or the formula -SO 2 -SO- - indicates, R 1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, R 2 is a carbon atom an alkyl group having 1-6, a cycloalkyl group having a carbon number of 3 to 8 atoms, R 3 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a hydrogen atom, R 4 is carbon an alkyl group having 1 to 6 atoms, a phenyl group, R 5 represents an alkyl group having 1 to 6 carbon atoms or a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, R 6 is phenyl I show a substituted phenyl group or a group. Have binding inhibitory activity of the Edg-1 (S1P1) and its receptor S1P, a pharmaceutically acceptable salt thereof or a compound represented by}, are useful as pharmaceuticals.式(I){式中、Aは硫黄原子、酸素原子、式-SO-又は式-SO2-を示し、R1は水素原子、炭素原子数1~6個のアルキル基等を示し、R2は炭素原子数1~6個のアルキル基、炭素原子数3~8個のシクロアルキル基等を示し、R3は水素原子、炭素原子数1~6個のアルキル基を示し、R4は水素原子、炭素原子数1~6個のアルキル基、フェニル基等を示し、R5は水素原子または炭素原子数1~6個のアルキル基を示し、R6は炭素原子数1~6個のアルキル基、フェニル基または置換フェニル基を示す。}で表される化合物またはその医薬上許容される塩は、S1Pとその受容体であるEdg-1(S1P1)との結合阻害作用を有し、医薬品として有用である。
